bioAffinity’s CyPath® Lung Test Detects Early Cancer

bioAffinity Technologies, Inc. ( (BIAF) ) has issued an update.

On July 29, 2025, bioAffinity Technologies announced a case study where their CyPath® Lung test successfully detected Stage 1A pulmonary mucinous adenocarcinoma in a high-risk patient whose previous tests indicated a low probability of cancer. This case highlights CyPath® Lung’s ability to provide diagnostic clarity in cases where traditional methods are inconclusive, potentially leading to earlier and more effective treatment options for patients.

The most recent analyst rating on (BIAF) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on bioAffinity Technologies, Inc. stock, see the BIAF Stock Forecast page.

Spark’s Take on BIAF Stock

According to Spark, TipRanks’ AI Analyst, BIAF is a Neutral.

The most significant factor affecting the score is the company’s poor financial performance, characterized by negative profitability and high leverage. Positive corporate events, including strategic patent awards and a sales agreement, offer some encouragement but are overshadowed by the financial instability and Nasdaq compliance challenges.

To see Spark’s full report on BIAF stock, click here.

More about bioAffinity Technologies, Inc.

bioAffinity Technologies, Inc. is a biotechnology company specializing in noninvasive diagnostics and early cancer detection, with a focus on lung diseases. Their flagship product, CyPath® Lung, is a noninvasive test that has demonstrated high sensitivity, specificity, and accuracy in detecting early-stage lung cancer, and is marketed as a Laboratory Developed Test by their subsidiary, Precision Pathology Laboratory Services.

Average Trading Volume: 7,354,911

Technical Sentiment Signal: Sell

Current Market Cap: $9.21M

See more insights into BIAF stock on TipRanks’ Stock Analysis page.